Montpellier-based biopharmaceutical company NFL Biosciences detailed strategic updates on its NFL-101 and NFL-102 smoking cessation programs on Tuesday, Oct. 6, 2026, aiming to secure upcoming licensing agreements with major pharmaceutical laboratories, Presse Agence reported.
The Euronext Growth Paris-listed firm announced scientific and regulatory milestones for both assets, which rely on immunotherapies derived from tobacco leaves to treat nicotine addiction through a two-injection subcutaneous regimen. The disclosures highlight progress in precision medicine approaches for NFL-101 alongside regulatory steps for the phase 2 study of NFL-102.
Post-Hoc Analysis Validates NFL-101 Biomarker
NFL Biosciences completed an in-depth post-hoc analysis of data from the CESTO2 clinical trial evaluating its primary candidate, NFL-101. The evaluation validated a predictive biomarker of efficacy designed to pinpoint patients most likely to experience positive treatment outcomes. A consortium of international researchers is finalizing a manuscript detailing these findings for submission to a leading scientific journal in the coming days.
Contributing experts include researchers from McLean Hospital, an affiliate of Harvard Medical School in Boston, the Centre for Addiction and Mental Health in Toronto, and the Georges-Pompidou European Hospital in Paris. Independent validation by these external institutions is intended to bolster the scientific visibility of the immunotherapy ahead of upcoming commercial partnership negotiations.
Phase 2 TONIC Study Awaits French Regulatory Green Light
For its secondary candidate, NFL-102, the company is awaiting clearance from French health authorities to initiate a phase 2 clinical trial named TONIC. The application was submitted in late July 2026 to the National Agency for the Safety of Medicines and Health Products and the Committee for Protection of Persons. Following responses to regulatory inquiries, NFL Biosciences anticipates a formal decision during November 2026.
The TONIC trial is designed to enroll 310 smokers to measure safety, determine optimal dosage, and evaluate efficacy. A preliminary data analysis involving the initial 40 participants is scheduled to capture early therapeutic indicators once the trial commences.
Preclinical Studies Measure Neurotransmitter Release and Brain Imaging
Basic research into the fundamental mechanisms of action supporting the treatments continues alongside clinical trials. The French Alternative Energies and Atomic Energy Commission is finalizing a manuscript covering brain imaging and proteomics results for submission in October 2026. A preclinical microdialysis study conducted at McLean Hospital and Harvard Medical School yielded positive initial results in late September, measuring neurotransmitter release within the brain to clarify the pharmacological impact of the immunotherapies.
Frequently Asked Questions About the Clinical Programs
What is the administration method for the NFL Biosciences treatments? Both NFL-101 and NFL-102 are designed to be administered in just two subcutaneous injections.
How many participants are planned for the NFL-102 TONIC trial? The phase 2 study will include 310 smokers, with an early analysis planned after the first 40 participants complete initial evaluations.
Which regulatory bodies are reviewing the NFL-102 trial application? The application is under review by the National Agency for the Safety of Medicines and Health Products and the Committee for Protection of Persons in France, with a decision anticipated in November 2026.
Worth a look
